



GE Healthcare

Level 11, 32 Phillip Street
Parramatta, NSW, 2150
Australia

Dear Valued Customer

May 2022

STOCK SHORTAGE- IODINATED CONTRAST MEDIA IN AUSTRALIA

Due to the lockdown imposed by local authorities to contain the current outbreak of Covid – 19 in the city of Shanghai our production facility in that city has experienced an unexpected shut down.

The facility is now operational again with skeleton staff with reduced capacity.

Of greater impact is the shutdown and delays to normal shipping and airfreight routes out of the city which means we are currently unable to ship finished goods to Australia on time.

We have taken measures to try to source product urgently from our Cork manufacturing plant and these contingency plans are still being investigated.

As a result, Omnipaque [iohexol] and Visipaque [iodixanol] supply has been affected for Australian customers and backorders are expected for 4 – 6 weeks during May/early June.

The situation is temporary, and we expect to return to normal service in Mid-June although this is still subject to confirmation that the Shanghai lock down has officially been lifted before 21 May.

Please be assured that we are continuing to do all we can to minimize this temporary disruption to your supply.

We have notified TGA of our supply shortages as required.

We will keep you informed. Please do not hesitate to contact me as your local account manager for updates or our customer service team at customerorders@ge.com

Yours sincerely,

A handwritten signature in black ink, appearing to be 'Marshall Leigh', written over a white background.

Marshall Leigh
National Sales Manger
Pharmaceutical Diagnostics
GE Healthcare
M; 0414 570 300
E; marshall.leigh@ge.com